Ca125 as a Marker for the Follow-up of Relapsing Polysierositis: A Case Report

Davide Onofrio Fontana1*, Claudio Pedone1,2 and Raffaele Antonelli Incalzi1,2,3
1Area di Geriatria, Policlinico Universitario Campus Bio-Medico, Roma, Italy
2Fondazione “Alberto Sordi”, Roma, Italy
3Fondazione “San Raffaele - Cittadella della Carità”, Taranto, Italy

Keywords: Peritoneal; Secretion; Malignant; Mucoproteins; Rheumatoid

Introduction

Ca125 is a well-known marker of many malignant and non-malignant diseases the majority of which are characterized by serosal involvement [1]. Mesothelial secretion of Ca125 rather than direct production by the neoplastic or inflammatory cells seems to underlie this phenomenon [2]. Thus, Ca125 qualifies as a marker of serosal, either peritoneal or pleural, involvement. Not surprisingly, rising levels of Ca125 have been reported to characterize recurrent polysierositis in the context of familiar Mediterranean fever or systemic lupus erythematous [3]. In these cases it was observed an increase in Ca125 concentration in patients with active disease, but Ca125 has not been used as marker of exacerbations.

We report a case of recurrent polysierositis in which exacerbations were heralded by increased Ca125 serum levels, making thus the periodical and on demand measurement of Ca125 a valuable means for a preclinical diagnosis of the recurrence.

Case Report

In November 2008 a 69 year old lady came to our attention for recurrent polysierositis. Her clinical history dated back to May 2008, when she was hospitalized elsewhere for fever, abdominal tension and dyspnea. Erythrocyte sedimentation rate was 23 mm/h, ferritin 341 mg/dl (normal values [n.v.]: 11-307 mg/dl), LDH 542 mg/dl (0-250 mg/dl), GGT 113 mg/dlU/l (n.v. 12-48 U/l), total bilirubin 2.3 mg/dl (n.v. 0-1.2 mg/dl), indirect bilirubin 1.8 mg/dl (0.0-0.4 mg/dl), Ca125 57 mg/dlU/ml (n.v. 0-35 U/ml). Mucoproteins were 187 mg/24H (n.v. 0-6 mg/24H), D-dimer 2338 mg/dl (n.v.<259 mg/dl). The HbsAg and HbsAb, HBe Ab, and HBcAb (IgG) were positive, as were the HAV Ab IgG. Anti-microbial antibodies and absence of antibodies against mitochondria.

In 2009, pleural and peritoneal effusions relapsed again, with observed values of 961 U/ml. A genetic study did not disclose MEFV mutation consistent with familial Mediterranean fever. The diagnosis of recurrent polysierositis was eventually confirmed and treatment with meth/prednisolone 24 mg started and, then, tapered gradually over 3 months.

Two months after steroid discontinuation, a new relapse occurred and responded well to a new course of steroids. Afterwards, the patients was carefully monitored for relapsing pleural or peritoneal effusion by recording the weight, and a course of corticosteroid was administered at first signs of relapses, which usually were abdominal "fullness", dyspnea, edema and low grade fever. Later on, Ca125 was measured every three months, and predniione was started when this marker at least doubled with regard to the last basal value, which occurred three times during one years, preventing thus the new onset of symptoms. This strategy has proved effective so far, although in the last couple of years the frequency of exacerbations has increased, with only about two weeks free of symptoms before a new treatment course is needed (Figure 1).

This case report confirms that Ca125 may be an indicator of the activity of polysierositis [4]. However, we add to the current knowledge by showing that exacerbations of recurrent polysierositis could be prevented and the related needs of steroids decreased by measuring Ca125 periodically and in the event of alarming symptoms such as feeling of rising abdominal tension and fatigue. The early intervention allowed to prevent or abort the exacerbation through a shorter course and lower cumulative dose of steroids. Furthermore, it prevented major symptoms such as abdominal pain, leg oedema and dyspnoea.

Interestingly, Ca125 increase also preceded the rise in inflammatory markers, as if activation of mesothelial cells were the first step of the exacerbation. Obviously, the timing of Ca125 monitoring was tailored to our patient and might not be the most appropriate for another patient.

*Corresponding author: Davide Onofrio Fontana, Area di Geriatria-Università Campus Bio-Medico, Via Alvaro del Portillo 200, 00128 Roma, Italy. Tel: +39 (06) 22541133; Fax: +39 (06) 225411028; E-mail: d.fontana@unicampus.it

Received April 30, 2015; Accepted August 12, 2015; Published August 14, 2015


Copyright: © 2015 Fontana DO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Molecular Biomarkers & Diagnosis
Thus, a careful scrutiny of clinical history is mandatory to correctly use this early diagnostic strategy.

This steroid sparing strategy is also important to prevent steroid related side effects. This is especially true in patients, such as ours, with very limited range of activity and ensuing greater risk of osteoporosis, sarcopenia and insulin resistance.

A note of caution in considering this case report is needed because we cannot exclude that Ca125 serum levels to some extent fluctuate. In this event, the risk exists that a spontaneous fluctuation and not an impending exacerbation accounts for increasing Ca125. Thus, a better knowledge of the dynamic of Ca125 would allow optimize the Ca125 based follow up strategy. Nevertheless, it is clear that in our patient monitoring Ca125 could improve the health status and reduce the use of steroids.

In conclusion, Ca125 might be an useful diagnostic tool to diagnose impending exacerbations of polyserositis at a preclinical stage and to guide the therapy accordingly. Experience is needed to translate a single, yet well documented, case into rules of general interest.

References

Submit your next manuscript and get advantages of OMICS Group submissions
Unique features:
• Increased global visibility of articles through worldwide distribution and indexing
• Showcasing recent research output in a timely and updated manner
• Special issues on the current trends of scientific research
Special features:
• 700 Open Access Journals
• 50,000 editorial team
• Rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
• Sharing Option: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/pharma